OUR BUSINESS

Business Model and Value Creation aligned to the Six Capitals

OUR BUSINESS

Our Business model demonstrates the six capitals (inputs), enables value-adding activities (outputs) that create, preserve or erode value for our stakeholders (outcomes)

Financial

Blood transfusion services
Receipts from debtors
- Private patients & institutions
- Government hospitals
Operating expenses
Capital expenditure
- IT (process automation)
- Innovation
- Patient Blood Management (PBM) supply/demand & inventory
Improved procurement practices/ processes

Intellectual

Brand, reputation
Research & development (innovative patient treatment)
Licence to operate
Scarce skills
Board experience
Academy
Drone capability
Achievement of ISO15189 & 100% SANAS accreditation across all sites
Well performing Board with succession plan, accounting skills bolstered on Audcom

Human

Manufactured

Donor pool (blood collection)
Almost 900 000 collections per year – but Covid-19 restrictions severely impacting
IT systems
- migration to eProgesa
- SAP ERP
SANBS sites
- 2 testing laboratories (Constantia Kloof and Mount Edgecombe)
- 83 blood banks
- 71 donation centres
- 7 processing centres
25 mobile donor vehicles (58 beds)

Donor – confidentiality of information
Cornerstone of Health Care Services (gift of life blood supplied, healthy donors & #IronStrong)
Transformation strategies
Stakeholder engagement

Natural

Red blood cells for transfusion
Fresh frozen plasma and Cryoprecipitate for patient use
Hyper-immune and recovered plasma for NBI
Pooled and Apheresis platelets for transfusion Platelet Immunology & Immuno-haematology testing Stem cell collection, processing, cryopreservation & re-infusing services Laboratory testing to facilitate solid organ, stem cell & bone marrow transplants
Molecular research & development

Being cognisant of our material matters, while managing key risks and opportunities and our strategic objectives (iHEALTh) – all underpinned by sound governance

Financial

Turnover R3.62 bn (FY21: R3.19 bn 13% increase YoY)
Increase in total collections: R3.58bn to R3.83 bn (7% YoY)
39.9 % (FY21: 44.7%) staff costs as % total costs
4.6 % (FY21: 6.7%) net surplus vs budgeted net surplus 1.7% (FY21: -2.4%)
Increased current ratio 5.7 (FY21:4.5)
Increased currency volatility impacts on procurement of imported consumables
Reduced collection & processing costs (Covid-19 impact)
Reduced courier costs (Covid-19 impact of reduced collections & processing)
Procurement contributed 48.6 points (FY21: 42.4) to SANBS B-BBEE score, now compliant on preferential procurement, supplier & enterprise development

Intellectual

Team members occupy honorary positions at leading institutions
World leading blood transfusion & blood products organisation
Further embedding of Purpose, Vision & Mission
PBM – fulfills purpose “Trusted to Save Lives”
Publications & development of authors
International working groups
Innovation: drone licencing, revenue from new income streams < budget due to Covid-19, CV Plasma trials, mobiles, smart fridges
R&D – clinical trials (CV plasma & Covid-19 anti-body studies) & funding grants
Well performing Board with succession plan, accounting skills bolstered on Audit Committee

Human

89 % black employees (FY21: 88%)
Strong focus on females 59 % female (FY21: 59%) - Board 55 % (FY21: 60%) & Exco 50 % (FY21: 43%)
Strong, competent & focused leadership team
Reduced overtime due to reduced collections & processing
SANBS Formula – minimal reduction in DNA score from 1.31 to 1.26. Pleasing increase of participants in survey Y-o-Y from 1 972 to 1997
Reduction in tip-offs & more transparent communication
Aspirational culture journey continues

Manufactured

Donors: increased post Covid-19
Doctors: Reduced blood supply cutbacks
PBM – increased efficiencies in available blood stock management
Mount Edgecombe site functional
Smart fridges deployed
Developed & launched mobile donor vehicles
Remote/work from home enabled for staff where practical
Increased donor reach/accessibility with 4 3xbed crafters and 1 4xbed POC trailer

Covid-19 effects on blood collection & issue – but continued unabated to saving lives & living our purpose
Compliance with all health/blood regulatory requirements
Advanced preparation for new regulations eg SAHPRA, NHI (participation – influencing & maximising opportunities it creates)
Positive impact on SA citizen health
Improved doctor experience (enough blood)
Improved implementation of B-BBEE initiatives – achieved level 4 status (FY21: Level 5)

Natural

… and ensures our ability to create value in the future